RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Results and Subgroup Analyses of the PETACC-8 Trial
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 15
SP 9
OP 9
DO 10.1177/155989771215004
UL http://mdc.sagepub.com/content/12/15/9.1.abstract
AB FOLFOX4 (leucovorin, 5-fluorouracil, and oxaliplatin) has been the standard adjuvant therapy for resected stage III colon cancer since 2004, producing 3-year disease-free survival rates of ∼70%. The aim of the Combination Chemotherapy with or Without Cetuximab in Treating Patients with Stage III Colon Cancer That Was Completely Removed by Surgery [PETACC-8; NCT00265811] trial was to assess the potential benefit of adding cetuximab to standard treatment for colon cancer.